Danaher Corporation Stock News

Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.

Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who

Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.

The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.

Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antib

Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with

Here's a sneak peek.

It's not often that you read about activist investor Dan Loeb praising the chief executive officer (CEO) of a company in which Third Point Management holds a stake, but that's precisely what happened

As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disruptions in

High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO's research shows tha

Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each ye

With a daily gain of 3.15% and Earnings Per Share (EPS) (EPS) of $8.52, Danaher Corp ( DHR , Financial) presents a compelling case for value investors. The question we aim to answer is: Is Danaher (DH

After a dismal 2022, investors have returned to the top growth stocks to buy with great enthusiasm. We shouldn't forget the lessons from 2022, however.

Danaher's (DHR) Q2 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.

CNBC's Jim Cramer delivers his daily Mad Dash.